Elevated Capital Advisors LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Elevated Capital Advisors LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,551 shares of the medical research company’s stock after purchasing an additional 55 shares during the period. Elevated Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $959,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG grew its stake in Thermo Fisher Scientific by 1.1% in the third quarter. Bank Pictet & Cie Europe AG now owns 152,696 shares of the medical research company’s stock worth $94,453,000 after purchasing an additional 1,657 shares during the period. Marietta Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 2.8% in the third quarter. Marietta Wealth Management LLC now owns 13,319 shares of the medical research company’s stock worth $8,239,000 after acquiring an additional 366 shares in the last quarter. Foresight Group Ltd Liability Partnership boosted its holdings in Thermo Fisher Scientific by 159.3% in the third quarter. Foresight Group Ltd Liability Partnership now owns 1,216 shares of the medical research company’s stock worth $752,000 after acquiring an additional 747 shares in the last quarter. GAM Holding AG boosted its holdings in Thermo Fisher Scientific by 2.2% in the third quarter. GAM Holding AG now owns 9,347 shares of the medical research company’s stock worth $5,782,000 after acquiring an additional 199 shares in the last quarter. Finally, Segment Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 2.0% in the third quarter. Segment Wealth Management LLC now owns 5,929 shares of the medical research company’s stock worth $3,668,000 after acquiring an additional 116 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on TMO shares. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Stephens started coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target on the stock. Bank of America upped their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $656.00.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $574.78 on Wednesday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88. The stock has a 50-day moving average price of $607.55 and a 200 day moving average price of $584.45. The stock has a market capitalization of $219.57 billion, a P/E ratio of 36.37, a P/E/G ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter last year, the business posted $5.15 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.